For decades, the prevailing model held that inflammation simply faded away once the offending stimulus was cleared — a passive dissipation of pro-inflammatory signals. That model was wrong. In 2000, Charles Serhan’s lab at Harvard discovered that resolution of inflammation is an active, programmed biochemical process driven by a distinct family of lipid mediators biosynthesized from omega-3 fatty acids. These molecules — collectively termed specialized pro-resolving mediators, or SPMs — fundamentally reframe how we understand both chronic inflammatory disease and the therapeutic value of EPA and DHA.
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are a superfamily of endogenous lipid mediators enzymatically derived from polyunsaturated fatty acids — primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA). The four major SPM families are resolvins (E-series from EPA, D-series from DHA), protectins (from DHA), maresins (macrophage mediators in resolving inflammation, from DHA), and lipoxins (the lone family derived from arachidonic acid).[1]
Unlike non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids — which suppress the initiation phase of inflammation — SPMs act in the resolution phase. They are produced via a programmed lipid mediator class switch: as acute inflammation peaks, the same biosynthetic machinery that produced pro-inflammatory leukotrienes and prostaglandins shifts to producing SPMs that terminate the response. This concept, established by Serhan and colleagues, redefined resolution as an active agonist-driven process rather than passive decay.[1][2]
How SPMs Work
Substrate Dependence on EPA and DHA: Every SPM (except lipoxins) requires omega-3 fatty acids as obligate biosynthetic precursors. EPA is converted via cytochrome P450 and 5-lipoxygenase pathways to E-series resolvins (RvE1, RvE2, RvE3). DHA is sequentially oxygenated by 15-lipoxygenase and 5-lipoxygenase to yield D-series resolvins (RvD1–RvD6), protectin D1, and maresin 1. Without sufficient tissue EPA and DHA, the body cannot generate adequate SPMs — which reframes omega-3 supplementation not as a passive anti-inflammatory but as substrate provisioning for an active resolution program.[2]
Receptor-Mediated Signaling: SPMs are not nonspecific antioxidants. They act through specific G-protein-coupled receptors at picomolar to nanomolar concentrations. RvE1 binds ChemR23 (ERV) and antagonizes BLT1. RvD1 binds ALX/FPR2 and GPR32. Maresin 1 acts through LGR6. Engagement of these receptors triggers defined intracellular cascades that limit neutrophil infiltration, stimulate macrophage efferocytosis, and restore tissue homeostasis.[3]
Efferocytosis Enhancement: A defining action of SPMs is augmentation of macrophage efferocytosis — the non-phlogistic clearance of apoptotic neutrophils. Without efficient efferocytosis, dying neutrophils undergo secondary necrosis, releasing damage-associated molecular patterns and perpetuating inflammation. Resolvins and maresins drive macrophage polarization toward a pro-resolving phenotype that engulfs cellular debris and produces additional SPMs in a positive feedback loop.[3][4]
Counter-Regulation Without Immunosuppression: Critically, SPMs limit neutrophil recruitment and pro-inflammatory cytokine production without suppressing host antimicrobial defense. In animal models of bacterial infection, RvD1 and protectin D1 actually accelerate bacterial clearance while reducing tissue damage — a profile that distinguishes SPMs from glucocorticoids, which broadly impair immunity.[4]
Clinical Evidence
Cardiovascular Disease: Plasma SPM concentrations are reduced in patients with peripheral artery disease and unstable atherosclerotic plaques. Conversely, the REDUCE-IT trial demonstrated that high-dose icosapent ethyl (purified EPA, 4 g/day) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides — an effect that mechanistic work has linked, in part, to enhanced E-series resolvin biosynthesis rather than triglyceride lowering alone.[5]
Periodontal and Oral Inflammation: Resolvin E1 has been studied extensively in periodontitis. Topical RvE1 in animal models reverses bone loss and restores tissue architecture, and human studies have correlated SPM levels with periodontal health.[3]
Pain and Neuroinflammation: SPMs — particularly RvD1, RvD2, and neuroprotectin D1 — exert potent analgesic effects in models of inflammatory and neuropathic pain at doses orders of magnitude lower than conventional analgesics, acting through both peripheral and central mechanisms involving TRPV1 modulation and microglial repolarization.[3]
Sepsis and ARDS: In experimental sepsis, SPM administration improves survival, accelerates bacterial clearance, and limits organ injury. Human plasma SPM profiles have been proposed as biomarkers distinguishing resolving from non-resolving inflammation in critical illness.[4]
Omega-3 Supplementation and SPM Levels: Multiple human trials have demonstrated that EPA/DHA supplementation raises circulating SPM concentrations in a dose-dependent manner, with measurable increases in 18-HEPE (the precursor to E-series resolvins) and 17-HDHA (the precursor to D-series resolvins and protectins) within hours to weeks of dosing.[2]
Safety Profile
Because SPMs are endogenous mediators acting at picomolar to low-nanomolar concentrations on specific receptors, their pharmacology differs fundamentally from broad-spectrum anti-inflammatories. Preclinical and early clinical work has not identified the immunosuppression, gastrointestinal toxicity, or cardiovascular risk associated with NSAIDs or steroids. EPA and DHA — the substrates from which SPMs are made — are well characterized in humans, with the major considerations being a modest dose-dependent increase in bleeding time at very high intakes and the rare possibility of atrial fibrillation signal observed in some high-dose EPA trials.[5]
Direct administration of synthetic SPMs remains investigational. Stability is a known challenge: native resolvins are rapidly inactivated by 15-prostaglandin dehydrogenase, prompting development of metabolically resistant analogs. For clinical practice today, the practical leverage point is ensuring adequate omega-3 substrate — typically 2–4 g/day of combined EPA/DHA — to support endogenous SPM biosynthesis.
SPMs vs Conventional Anti-Inflammatory Approaches
vs NSAIDs: NSAIDs inhibit cyclooxygenase, blocking prostaglandin synthesis. This suppresses the initiation of inflammation but does not promote resolution. Paradoxically, COX inhibition can impair lipoxin biosynthesis and delay resolution. SPMs act downstream, terminating inflammation that has already begun without blocking initiation.[1]
vs Corticosteroids: Glucocorticoids broadly suppress immune function and carry significant metabolic, skeletal, and infectious risks with chronic use. SPMs accelerate resolution while preserving — and in some contexts enhancing — antimicrobial defense.[4]
vs Generic Omega-3 Supplementation: The SPM framework reframes EPA and DHA: their value lies not in displacing arachidonic acid in cell membranes but in serving as obligate substrates for an active resolution program. This explains why higher, pharmacologic doses of purified EPA (as in REDUCE-IT) produced clinical effects that lower-dose general fish oil trials did not.[5]
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Chiang N, Dalli J. “The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution.” Seminars in Immunology. 2015;27(3):200-215.
- Chiang N, Serhan CN. “Specialized pro-resolving mediator network: an update on production and actions.” Essays in Biochemistry. 2020;64(3):443-462.
- Dalli J, Serhan CN. “Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators.” Blood. 2012;120(15):e60-e72.
- Bhatt DL, Steg PG, Miller M, et al. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.” New England Journal of Medicine. 2019;380(1):11-22.
